| Identification | Back Directory | [Name]
FLECAINIDE ACETATE | [CAS]
54143-56-5 | [Synonyms]
FLAC
r-818
Apocard
Ecrinal
Tambocor
Almarytm
Flucarney Acetate
FLECAINIDE ACETATE
Flecainide-d4 Acetate
Flecainide acetate CRS
FLECAINIDE ACETATE SALT
Flecainide Acetate (200 mg)
FLECAINIDE ACETATE USP/EP/BP
Flecainide acetate (F0120000)
Flecainide for system suitability
Flecainide for system suitability CRS
Flecainide for system suitability (Y0001274)
2,5-Bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide acetate
N-(2-PIPERIDYLMETHYL)-2,5-BIS-(2,2,2-TRIFLUOROETHOXY)BENZAMIDE ACETATE
2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidinylmethyl)benzamideacetate
N-[2-Pyperidinylmethyl]-2,5-bis[2,2-2-trifluoroethoxy] benzamide acetate
n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamidemonoacetate
n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-benzamidmonoacetate
N-[2-PIPERIDYLMETHYL]-2,5-BIS-[2,2,2-TRIFLUOROETHOXY]BENZAMIDE ACETATE SALT
N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide monoacetate
N-[[(2S)-2-piperidin-1-iumyl]methyl]-2,5-bis(2,2,2-trifluoroethoxy)benzamide
Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate
N-[(RS)-(Piperidin-2-ylmethyl)]-2,5-bis(2,2,2- trifluoroethoxy)benzamide acetate
Flecainide acetate salt,N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate salt
Flecainide acetateQ: What is
Flecainide acetate Q: What is the CAS Number of
Flecainide acetate Q: What is the storage condition of
Flecainide acetate Q: What are the applications of
Flecainide acetate | [EINECS(EC#)]
258-997-5 | [Molecular Formula]
C19H24F6N2O5 | [MDL Number]
MFCD00214290 | [MOL File]
54143-56-5.mol | [Molecular Weight]
474.39 |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, very hygroscopic, crystalline powder. | [Melting point ]
145-147℃ | [storage temp. ]
2-8°C
| [solubility ]
Soluble in water and in anhydrous ethanol. It is freely soluble in dilute acetic acid and practically insoluble in dilute hydrochloric acid. | [form ]
neat | [color ]
White | [Water Solubility ]
Soluble in dilute acetic acid, dimethyl sulfoxide, ethanol, methanol and water. | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 1 month. |
| Hazard Information | Back Directory | [Chemical Properties]
White or almost white, very hygroscopic, crystalline powder. | [Uses]
Class I antiarrhythmic. | [Definition]
ChEBI: An acetate salt obtained by combining flecainide with one molar equivalent of acetic acid. An antiarrhythmic agent used to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart). | [Brand name]
Tambocor
(3M Pharmaceuticals). | [Biological Activity]
Open Na + channel blocker that inhibits fast Na + current in cardiac muscle in a use and concentration-dependent manner. Orally-active class Ic antiarrhythmic agent. | [Description]
Flecainide acetate (54143-56-5) is an open Na+?channel blocker that inhibits fast Na+?current in cardiac muscle in a use- and concentration-dependent manner.1?Orally-active class Ic antiarrhythmic agent2,3. Inhibits hERG potassium channels at clinically relevant concentrations.4 | [General Description]
Flecainide acetate, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)benzamide monoacetate(Tambocor), is a class IC antiarrhythmic drug withlocal anesthetic activity; it is a chemical derivative of benzamide.The drug undergoes biotransformation, forming ameta-O-dealkylated compound, whose antiarrhythmic propertiesare half as potent as those of the parent drug, and ameta-O-dealkylated lactam of flecainide with little pharmacologicalactivity. Flecainide acetate is given orally to suppresschronic ventricular ectopy and ventricular tachycardia.It has some limitations because of CNS side effects. | [Biochem/physiol Actions]
Class IC antiarrhythmic agent; sodium channel blocker | [Clinical Use]
#N/A | [Drug interactions]
Potentially hazardous interactions with other drugs
Anti-arrhythmics: concentration increased by
amiodarone - halve dose of flecainide; increased
myocardial depression with other anti-arrhythmics.
Antidepressants: concentration increased by
fluoxetine; increased risk of ventricular arrhythmias
with tricyclics.
Antihistamines: increased risk of ventricular
arrhythmias with mizolastine - avoid.
Antihypertensives: increased myocardial depression
and bradycardia with beta-blockers; increased
myocardial depression and asystole with verapamil.
Antimalarials: concentration increased by quinine;
avoid with artemether/lumefantrine.
Antimuscarinics: increased risk of ventricular
arrhythmias with tolterodine.
Antipsychotics: increased risk of ventricular
arrhythmias with antipsychotics that prolong the
QT interval and phenothiazines; increased risk of
arrhythmias with clozapine.
Antivirals: concentration possibly increased by
fosamprenavir, indinavir, lopinavir, ritonavir and
saquinavir, increased risk of ventricular arrhythmias
- avoid; use telaprevir with caution.
Diuretics: increased cardiac toxicity if hypokalaemia
occurs. | [Metabolism]
Flecainide is extensively metabolised (subject to genetic
polymorphism), the 2 major metabolites being m-Odealkylated flecainide and m-O-dealkylated lactam of
flecainide, both of which may have some activity. Its
metabolism appears to involve the cytochrome P450
isoenzyme CYP2D6, which shows genetic polymorphism.Flecainide is excreted mainly in the urine, approximately
30% as unchanged drug and the remainder as metabolites.
About 5% is excreted in the faeces. Haemodialysis
removes only about 1% of unchanged flecainide. | [storage]
Desiccate at +4°C | [References]
1) Rouet and Ducouret (1994), Use- and concentration-dependent effects of flecainide in guinea pig right ventricular muscle; J. Cardiovasc. Pharmacol.,?24?177
2) Singh?et al. (1984),?The electrophysiology and pharmacology of verapamil, flecainide, and amiodarone: correlations with clinical effects and antiarrhythmic actions; Ann. N.Y. Acad. Sci.,?432?210
3) Banitt?et al.?(1977),?Anti-arrhythmics. 2. Synthesis and antiarrhythmic activity of N-(piperidylalkyl)trifluoroethoxybenzamides; J. Med. Chem.,?20?821
4) Melgari?et al.?(2015),?Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide; J. Mol. Cell. Cardiol.,?86?42 |
|
|